A Phase 1 study of TOP1288, our lead programme for ulcerative colitis, is on track to report data from healthy volunteers and patients in H1 2016.
Exciting technology platform - next generation kinase inhibitors
Our Narrow Spectrum Kinase Inhibitors (NSKIs) are novel small molecules which specifically target a select range of kinases that mediate inflammatory disease and have topical, non-systemic availability to provide long-term safety and tolerability.
Targeting areas of high unmet need
TOP1288 is being developed for ulcerative colitis, a disease in which first line therapy fails in 50% of patients, and 20% require major colon surgery.
High quality team
Our experienced management team works alongside selected experts in their field
Blue chip investors
Our investors include Imperial Innovations, SV Life Sciences and NeoMed alongside a strategic investment made by Johnson and Johnson Development Corporation
TopiVert is a private, clinical-stage biotechnology company developing next-generation, Narrow Spectrum Kinase Inhibitors (NSKIs) as novel, non-systemic medicines for the treatment of chronic inflammatory diseases of the gastrointestinal (GI) tract and the eye.
"We aim to change the lives of millions of people around the world suffering with serious diseases such as inflammatory bowel disease and dry eye disease, both areas with high unmet medical needs"
Hamish Cameron, Chairman of TopiVert
NSKIs are novel small molecules characterised by broad efficacy and an excellent safety profile. Each NSKI has potent activity against a select range of key kinases that play pivotal roles in multiple inflammatory pathways and has resulted in a broad synergistic effect in models of both innate and adaptive immunity. NSKIs also have non-systemic bioavailability, such that their activity is focused at the local site of disease. Together, these attributes make NSKIs ideally adapted as treatments for inflammatory diseases where long-term therapy demands a sustained effect along with high safety and tolerability.
We are using our NSKI technology to develop improved treatments for chronic inflammatory diseases of the GI tract and the eye. Our most advanced drug candidate, TOP1288 for the treatment of ulcerative colitis, is in Phase 1 clinical development and data from both healthy volunteers and patients is expected in H1 2016 ahead of a planned Phase 2a proof-of-concept (POC) study later in the year . We are also planning to commence the clinical development of our lead ophthalmology product, TOP1630 in dry eye disease, in late 2016.
Our high quality science and management team are backed by blue-chip investors. Learn more about who we are, what we are doing and what drives us forward.